



Echanges gazeux appliqués à la CEC

Prof. Alexandre OUATTARA
Service d'Anesthésie-Réanimation cardiovasculaire
Hôpital Haut-Lévêque hospital
33600 Pessac, France
E-mail: alexandre.ouattara@chu-bordeaux.fr




Respiration cellulaire



PRIMUM MOVENS CELLULAIRE

Les échanges gazeux entre l'air ambiant et la cellule sont assurés par...

LA POMPE CARDIO-THORACIQUE




PHASE GAZEUSE => LOI DE DALTON (LOI DES PRESSIONS PARTIELLES)

- Tout gaz d'un mélange exerce une pression partielle proportionnelle à sa fraction (assimilée à son pourcentage)
- Pression partielle P d'un gaz donné « x » est égale au produit de la pression totale, P_T, par la fraction F_x de ce gaz dans le mélange
- Somme des pressions partielles est égale à la pression totale du mélange

$$P_x = P_T \times F_x \leftrightarrow P_x = P_B \times F_x$$




Composition de l'air ambiant

Gaz	Fraction (%)	Pression partielle (mmHg)
N ₂	78.6	597
O ₂	20.9	159
CO ₂	0.04	0.3
H ₂ O	0.46	3.7
Total	100%	760



$$P_{GAS} = \text{Fraction} \times P_{atmosphérique}$$

$$P_{ATM} = 760 \text{ mmHg au niveau de la mer}$$



ETAPE PULMONAIRE: TRANSFERT DES GAZ

- IMPLIQUE**
 - phase gazeuse et liquidienne (sang)
 - séparées par la membrane alvéolo-capillaire
- DEPEND**
 - de la composition de l'air alvéolaire
 - de la diffusion
 - rapports ventilation-perfusion

Diffusion des gaz

Gas Exchange within Alveoli

Loi de Fick de Diffusion

$$\text{Rate of gas diffusion} = k_{\text{gas}} \times A \times \frac{\Delta P_{\text{gas}}}{D}$$

k_{gas} : constante de diffusion (gas dépendante)

A : surface d'échange

D : épaisseur de la membrane

Delta P_{gas} : gradient de pression partielle entre l'alvéole et le sang capillaire pulmonaire (gas dépendant)

Rapport ventilation-perfusion


Zone de West I-III

Zone I = PA > Pa > Pv


Zone II = Pa > PA > Pv

Zone III = Pa > Pv > PA

Temps de transit dans la barrière alvéolo-capillaire (effet PvO_2)




Bronchial artery perfusion during cardiopulmonary bypass does not prevent ischemia of the lung in piglets: assessment of bronchial artery blood flow with fluorescent microspheres



Schlensak C et al. Eur J Cardioth Surg 2001; 19:329-32

Schlensak C et al. J Thorac Vasc Surg 2002;123:1199-205




Contenu de l'oxygène dans le sang

$CaO_2 = O_2$ transporté par Hb + O_2 dissous



$$CaO_2 = (SaO_2 \times Hb \times 1,34) + PaO_2 \times 0,003$$

1 gramme d'Hb fixe 1,34 mL d' O_2


Coefficient de solubilité de l' O_2 dans le sang (en mL d' O_2 /L sang/mmHg)









Courbe de BARCROFT




EFFET BOHR*



Physiologiste Danais (1904)



TRANSPORT EN CO₂




EFFET HALDANE

Fixation du CO₂ à l'hémoglobine (extrémités NH₂)

Pour une valeur de PCO₂ donnée, le sang contient d'autant plus de CO₂ lié à l'hémoglobine qu'il est riche en hémoglobine réduite (non liée à l'oxygène = desoxyhémoglobine) et donc du sang veineux.



C'est l'effet HALDANE





Diffusion tissulaire

- Deux étapes, au travers:
 - Capillaire systémique
 - Espace péri-capillaire


CO₂ est 21 fois plus diffusible que O₂ +++



Tsai et al. Physiol Rev 2003



INFLUENCE DE LA P50 SUR OXYGÉNATION TISSULAIRE






$$DO_2 = DC \times [(Hb \times SaO_2 \times 1.36) + PaO_2 \times 0.003]$$



$$VO_2 = DC \times (CaO_2 - CvO_2)$$

$$ERO_2 = VO_2 / DO_2$$


$$EO_2 = I - SvO_2$$



Adaptation TaO_2/VO_2




SvO_2 : FACTEURS DÉTERMINANTS



HO km et al. Shock 2008;29:3-6

VENOUS OXYGEN SATURATION



After ventilation with 100% inspired oxygen for 5 min




FIG. 1. Changes in mean of mixed (SvO_2) and central (CvO_2) venous oxygen saturation with changes in arterial oxygen tension in 20 critically ill patients with circulatory failure.

Goal-directed perfusion to reduce acute kidney injury: A randomized trial

[Check for updates](#)

2018

Marco Ranucci, MD, FESC,¹ Ian Johnson, CCP,^{2,3} Timothy Wilcox, CCP,^{2,3} Robert A. Baker, PhD, CCP,⁴ Christa Boer, MD, PhD,^{5,6} Andreas Baumann, MD,⁷ George A. Joviss, CCP,^{8,9} Filip de Somer, CCP,¹⁰ Paul Exton, BSc (Hon) ACP,¹¹ Seema Agarwal, FRCA,¹² Rachel Packer, PhD,¹³ Richard F. Newland, CCP,¹⁴ Renard G. Haumann, CCP,¹⁵ Dirk Buchwald, PhD, CCP,¹⁶ Nathan Weitzel, MD,¹⁷ Rajamir Venkateswaran, MD FRCS(Ch),¹⁸ Federico Ambrogio, PhD,¹⁹ and Valeria Pistuddi²⁰


ABSTRACT

Objective: To determine whether a goal-directed perfusion (GDP) strategy aimed at maintaining oxygen delivery (DO_2) at $\geq 280 \text{ mL} \cdot \text{min}^{-1} \cdot \text{m}^{-2}$ reduces the incidence of acute kidney injury (AKI).

Methods: This multicenter randomized trial enrolled a total of 350 patients undergoing cardiac surgery in 9 institutions. Patients were randomized to receive either GDP or conventional perfusion. A total of 326 patients completed the study and were analyzed. Patients in the treatment arm were treated with a GDP strategy during cardiopulmonary bypass (CPB) aimed to maintain DO_2 at $\geq 280 \text{ mL} \cdot \text{min}^{-1} \cdot \text{m}^{-2}$. The perfusion strategy for patients in the control arm was factored on body surface area and temperature. The primary endpoint was the rate of AKI. Secondary endpoints were intensive care unit length-of-stay, major morbidity, red blood cell transfusions, and operative mortality.

Results: Acute Kidney Injury Network (AKIN) stage 1 was reduced in patients treated with GDP (relative risk [RR], 0.45; 95% confidence interval [CI], 0.25-0.83; $P = .01$). AKIN stage 2-3 did not differ between the 2 study arms (RR, 1.66; 95% CI, 0.64-4.32; $P = .328$). There were no significant differences in secondary outcomes. In a prespecified analysis of patients with a CPB time between 1 and 3 hours, the differences in favor of the treatment arm were more pronounced, with an RR for AKI of 0.49 (95% CI, 0.27-0.89; $P = .017$).

Conclusions: A GDP strategy is effective in reducing AKIN stage 1 AKI. Further studies are needed to define perfusion interventions that may reduce more severe levels of renal injury (AKIN stage 2 or 3). (J Thorac Cardiovasc Surg 2018;156:1918-27)



ECHANGE GAZEUX EXTRA-CORPORELS

- "Un poumon simplifié" = oxygénateur.
- Principe de la membrane: interface entre sang et gaz.
- Large surface de diffusion: supérieure aux besoins standards en CEC
- Permet une relative tolérance de l'hémodilution.

	Poumon	Oxygénateur
Surface d'échange	100-150 m ²	1-4 m ²
Surface/volume	300 cm ³	28 cm ³
Distance de diffusion	1-2 µm	10-30 µm
Échange gazeux pour O ₂	210-3200 ml/min	200-400 ml/min

OXYGÉNATEUR

- Permet l'oxygénation et la **décarboxylation** du sang veineux.
- +/- administration agents anesthésiques inhalés.
- En aval de la pompe artérielle car résistance à l'écoulement.
- Technique moderne : oxygénateur à **MEMBRANES** :
 - évite contact air / sang.
 - moindre traumatisme des éléments sanguins.
 - risque d'embolie gazeuse quasi nul.
- Echanges gazeux par **DIFFUSION**: basés sur la différence en pression partielle du gaz entre la phase sanguine et la phase gazeuse.
- Echanges thermiques par **CONDUCTION**: entre 2 fluides (sang et eau).

MEMBRANES

POLYPROPYLENE




Figure 1: Typical hollow fiber design with a direct gas to blood interface through an open pore.

CEC

Fuite plasmatique et dégradation des échanges si > 6 heures

POLYMETHYLPENTHENE





Figure 2: Gas exchange by diffusion through a semi-permeable membrane.



ECMO+++

Hémocompatible, durée de vie supérieure
Imperméable aux halogénés



Oxygénation

- Peu dépendante du débit de gaz.
- Dépendante :
 - de la **FdO₂** du mélange gazeux.
 - du **DEBIT DE SANG** (notion de débit sanguin corrigé ou rated flow : débit max de sang 75% - 95%).
 - des caractéristiques de la membrane : coefficient de diffusion et surface de contact.
 - de l'état de la membrane (thrombose).
 - de la [Hb] et de la SaO₂ de l' Hb d' entrée (gradient).




Décarboxylation

Débit de sang (non limitant, 25% du débit physiologique suffit).


•Dépendante :

- du DEBIT DE GAZ (BALAYAGE ou sweep gas).
- du gradient de diffusion (PaCO₂ d'entrée).
- des caractéristiques de la membrane (surface...).

GAZ FRAIS



Kirson et al. J Cardiothorac Vasc Anesth, 1994




MONITORAGE GAZ DU SANG

- 1) Spectrophotométrie par réflexion
→ saturation sanguine en O₂
- 2) Capteurs électrochimiques
→ pressions partielles O₂ & CO₂
→ pH
→ autres paramètres : K⁺
- 3) Mesure répétées des GDS



VCO₂ MEASURED IN REAL TIME ON CPB CIRCUIT



$$V_{CO_2} \text{ indexed (mL} \cdot \text{min}^{-1} \cdot \text{m}^2) = \frac{e_{CO_2}(\text{mm Hg}) \cdot V_e(\text{L/min})}{760 \cdot BSA(\text{m}^2)}$$

CO₂ DERIVED PARAMETERS?

- CO₂ is the final product of cellular metabolism
- In **aerobic conditions**, CO₂ is produced by the Krebs cycle proportionally to oxygen consumption (respiratory quotient VCO₂/VO₂ ≈ 0.8)
- In **anaerobic conditions**, a decrease in VCO₂ is observed and related to a decrease in VO₂. Because CO₂ anaerobic production (residual hydrolysis ATP into ADP and neutralization H⁺ from lactic acid synthesis by bicarbonate ion), the decrease is proportionally less. Consequently, **an increase in VCO₂/VO₂ ratio is observed**.

BTPS (Body Temperature and Pressure, Saturated) vers STPD (Standard Temperature and Pressure, Dry)

Production de CO₂ (VCO₂) :

$$VCO_2 \text{ en mL/min} = VE \text{ en L/min} \times 1000 \times (P_{ECO_2} \text{ en mmHg} / (P_B - P_{H_2O}) \text{ en mmHg})$$

Conversion du volume de gaz mesurée aux conditions BTPS aux conditions STPD

Application loi des Gaz parfaits

$$\frac{\text{Pression} \times \text{Volume}}{T \text{ (kelvin)}} = \text{Constante}$$

$$\frac{P_{STPD} \times V_{STPD}}{T_{STPD}} = \frac{V_{BTPS} \times P_{BTPS}}{T_{BTPS}} \text{ donc } V_{STPD} = \left[\frac{P_{BTPS} \times T_{STPD}}{T_{BTPS} \times P_{STPD}} \right] \times V_{BTPS}$$

Facteur correcteur K de BTPS en STPD (VCO₂ corrigée)

$$V_{STPD} = \left[\frac{P_{BTPS} \times T_{STPD}}{T_{BTPS} \times P_{STPD}} \right] \times V_{BTPS}$$

$$V_{STPD} = \frac{(760 - P_{H_2O}) \times 273}{(273 + T^\circ) \times 760} \times V_{BTPS}$$

Facteur correcteur K1 de BTPS en STPD (VCO₂ corrigée)

T° température du compartiment gazeux (ligne artérielle)

Influence de la température sur le coefficient K de conversion de BTPS en STPD

Temperature (°C)	K ₁
32	0.853
34	0.842
35	0.837
37	0.826



Volume STPD est toujours plus petit que volume BTPS
VCO₂ corrigée toujours plus faible que la VCO₂ mesurée sur évent (K₁ < 1)

Quel niveau d'oxygénation au cours de la CEC?


TERMINOLOGIE

- **Hyperoxémie ou hypoxémie** = teneur en oxygène dans sang
- **Hyperoxie ou hypoxie** = teneur en oxygène dans tissu
- Hyperoxémie ne se traduit pas obligatoirement une hyperoxie
- Hypoxie tissulaire peut se voir sans hypoxémie

CASCADE DES PO₂



EFFETS HEMODYNAMIQUES DE L'HYPEROXIE




Haque WA et al. J Am Coll Cardiol 1996; 27:353-7

HYPEROXIE ET CIRCULATION CORONAIRE

Patients (n=27) bénéficiant d'un cathétérisme cardiaque
O₂ pur durant 15 min (**273±43 mmHg**)

	Blood O ₂ Content, ml/l		Art-CS O ₂ Content Difference, ml/l	Cardiac Vo ml/min
	Art	CS		
Room air	181 ± 24	62 ± 20	119 ± 26	5.2 ± 0.6
100% Oxygen	194 ± 22*	73 ± 21*	120 ± 23	3.8 ± 0.4*




HYPEROXEMIE ET MICROCIRCULATION

Etude animale (hamster)
O₂ pur pendant 30 min
Etude microvasculaire

Table 1. Systemic parameters and blood gas analysis during baseline and 100% O₂ inspiration

	Baseline	100% O ₂
Blood pressure, mmHg	88.3 ± 6.4	87.7 ± 7.1
Heart rate, beats/min	42.0 ± 28.3	39.0 ± 26.8
Arterial PO ₂ , mmHg	40.0 ± 1.2	47.9 ± 1.8
Arterial PO ₂ , mmHg	59.8 ± 4.1	64.3 ± 3.2
Arterial pH	7.36 ± 0.02	7.35 ± 0.01
Venous PO ₂ , mmHg	21.7 ± 7.1	26.4 ± 3.3
Venous PO ₂ , mmHg	70.4 ± 2.8	82.9 ± 3.5
Venous pH	7.33 ± 0.01	7.27 ± 0.03*
Cardiac index, ml·min ⁻¹ ·kg ⁻¹ (normalized to baseline)	196 ± 13	144 ± 31
Vascular resistance (normalized to baseline control)	(1.00 ± 0.00)	(0.75 ± 0.07)
Vascular resistance (normalized to baseline control)	0.46 (1.00)	0.61 (1.33)

Values are means $\pm$ SE. * P < 0.05 (statistically significantly different from baseline). Numbers in parentheses refer to results normalized to control.



Tsai AG et al. Am J Physiol Heart Circ Physiol 2003

EFFETS DE L'HYPEROXIE SUR OXYGENATION MUSCULAIRE

Patients de chirurgie cardiaque (n=10)
Mesure de la pression partielle musculaire en O₂ au cours de l'hyperoxémie (83-108 mmHg versus 281-356 mmHg)

Clinical course. No positive bacterial cultures from the electrode application sites or clinical complications from that site were seen. Similarly no other clinical complications were noted.


Discussion

In this study hyperoxemia increased global oxygen delivery and oxygen saturation in mixed venous blood during CPB. This effect might be assumed to provide improved tissue oxygenation and safety.

Tissue oxygenation. A common pattern of change from normoxemia to hyperoxemia was an increase in distribution heterogeneity of

Joachimsson PO et al. J Thorac Cardiovasc Surg 1996;112:812-9

PRODUCTION ESPÈCES RÉACTIVES DE L'OXYGÈNE (STRESS OXYDATIF)



Nakane M J Intensive Care 2020; 8:95

HYPEROXEMIE ET MICRO-BULLES

- Accélération dissolution microbulles
- Effet dénitrégation (azote moins soluble que l'oxygène)

Nollert G et al. J Thorac Cardiovasc Surg 1999; 117: 1166-71

ETUDE CLINIQUE III: TROUBLES DU RYTHME POST-OPERATOIRES

Patients opérés d'une chirurgie cardiaque sous CEC (>18 ans)
CEC normothermique (>36° C)

PaO₂ < 150 mmHg avec possibilité d'augmenter la FIO₂ si
SvO₂ < 60% (n=167)


versus

FIO₂ = 100% durant toute la CEC (n=163)

CJP= Troubles du rythme dans les 15 jours postopératoires (ACFA/FV/TV)

CJS= Morbi-mortalité postopératoire

Abou-Arab O et al. Intensive Care Med 2019; 45:1413-21



Type of event	Standard group (n=163)	Intervention group (n=161)	Absolute risk difference (intervention-standard)	p value
Primary endpoint				
PAOF or VTAF (n, %)	49 (30)	49 (30)	0.0% [-9.5;10.4]	0.94
POAF (n, %)	48 (29)	47 (29)	0.0% [-9.5;10.2]	0.94
VTAF (n, %)	4 (2)	4 (2)	0.0% [-3.3;3.4]	0.99

Type of event	Standard group (n=163)	Intervention group (n=161)	Absolute risk difference (intervention-standard)	p value
Secondary endpoints				
MACCE (n, %)	34 (21)	39 (24)	3.4% [-5.7;12.5]	0.47
Outcomes (n, %)				
Cardiac arrest	2 (1)	3 (2)	0.6% [-2.0;3.3]	0.64
In-hospital mortality	0 (0)	4 (2)	2.5% [0.08;6.3]	0.06
Acute kidney injury	30 (18)	35 (22)	3.3% [-5.4;12.0]	0.45
Stroke	2 (1)	1 (1)	-0.6% [-2.7;1.5]	0.57
Mesenteric ischemia	0 (0)	2 (1)	1.2% [-0.5;2.9]	0.25
Cardiac troponin (ng/L)				
6 h post CPB	7.4 [4.3-14.4]	8.0 [4.3-15.4]	-	0.79
Day 1 post CPB	4.3 [2.5-8.0]	4.6 [2.8-8.4]	-	0.53
Day 2 post CPB	1.9 [1.4-2.9]	2.0 [1.4-3.7]	-	0.80
Noxaprepine (n, %)	60 of 153 (39)	47 of 156 (30)	-3.1% [-19.7;13.5]	0.10
Debutamine (n, %)	11 of 153 (7)	10 of 156 (6)	-0.7% [-3.7;1.9]	0.81
ICU discharge (days)	2 [2-3]	2 [2-3]	-	0.94
Hospital discharge (days)	11 [9-14]	10 [9-12]	-	0.09
Out-of-hospital mortality at month 6	3 (2)	0 (0)	-	0.08

Table 3. Study Outcomes

	Hyperoxia (n = 49)	Normoxia (n = 51)	P Value
Delirium	15 (30.6)	16 (31.3)	0.93
Delirium severity (worst)	11 (8-13)	8 (7-11)	0.23
Time to delirium	1 (1-2)	2 (1-3)	0.17
Time characteristics			
Hospital length of stay, days	8 (5-11)	7 (5-10)	0.70
Intensive care unit length of stay, days	2 (1-3)	1 (1-3)	0.34
Hours of initial intubation	4.8 (3.7-6.7)	5.5 (3.7-6.7)	0.76
Adverse clinical outcomes			
Mortality			
In-hospital	0 (0)	0 (0)	
After 30 days	0 (0)	1 (1.96)	0.32
After 6 months	0 (0)	1 (2.56)	0.37
Stroke	0 (0)	0 (0)	
Pneumonia	3 (6.12)	1 (1.96)	0.36
Renal failure	0 (0)	1 (1.96)	0.32
Reoperation (bleeding)	0 (0)	1 (1.96)	0.32
Atrial fibrillation	14 (28.57)	16 (31.37)	0.83

ETUDE CLINIQUE II: FONCTION COGNITIVE

Patients opérés de PAC isolé (>65 ans)

FiO₂ 35% (PaO₂ >70 mmHg et SpO₂ >92%) avant CEC
et PaO₂ entre 100 et 150 mmHg durant CEC (n=51)



versus

FiO₂= 100% durant toute la chirurgie (n=49)


CJP= Montreal Cognitive Assessment Score (J2 postopératoire)

CJS= MCAS à M1, M3, M6 et morbi-mortalité postopératoire

Shaefi A et al. *Anesthesiology* 2021;134:189-201



QUELLE CIBLE? LES AVIS DIVERGENT...



« Too low » value?
Perfu = 100 mmHg
MAR = 60 mmHg

Calhoun A et al. *J Cardiothorac Vasc Anesth* 2022



European Journal of Cardio-Thoracic Surgery 00 (2019) 1–42
doi:10.1093/ejcts/ezy267



2019 EA/ECTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery

Authors/Task Force Members: Alexander Wahba^{AB,17} (Chairperson) (Norway), Milan Mijovic^{14,17} (Serbia, Netherlands), Christa Boer¹⁸ (Netherlands), Filip M.J. De Somer¹⁹ (Belgium), Tomas Gudbjartsson⁴ (Iceland), Jenny van den Groot²⁰ (Netherlands), Timothy J. Jones²¹ (UK), Vladimir Lomivorotov¹ (Russia), Frank Merkle²² (Germany), Marco Ranucci²³ (Italy), Gudrun Kunst²⁴ (Chairperson) (UK) and Luc Pui²⁵ (Chairperson) (Belgium)

7.14.2 Pharmacological interventions.

7.14.2.1 Hyperoxia. Exposure of the alveolus to 100% oxygen leads to alveolar collapse and the generation of oxygen radicals, which might exacerbate ischaemia-reperfusion injury after CPB. Small RCTs assessed the effect of hyperoxia on postoperative ventilation times, with conflicting results, demonstrating prolonged ventilation times with intraoperative hyperoxia in 1 RCT but not in others [304]. The lengths of the stays in the critical care unit and in the hospital were not affected [304].

CONCLUSION

- Hyperoxémie est souvent argumentée dans un souci sécuritaire en CEC
- Elle ne s'accompagne pas obligatoirement d'une hyperoxie tissulaire (impact micro-circulatoire)
- Effets potentiels délétères via le stress oxydatif induit (dommage cellulaire)
- Impact en pratique clinique?
- Cible **100-120 mmHg QSP > 96%**
- Meilleure interprétation SvO₂
- Hyperoxémie discutable en pré-CEC (induction anesthésique)

Recommendation Table 41 Recommendations for pump flow management during cardiopulmonary bypass

Recommendations	Class ^a	Level ^b	Ref ^c
It is recommended that the estimated pump flow rate be determined before the initiation of CPB based on the SGA and the planned level of hypothermia.	I	C	-
The adequacy of the pump flow rate during CPB should be considered based on oxygenation and metabolic parameters (pVO ₂ , SvO ₂ , iLDO ₂ , VCO ₂ /VQO ₂ , and arterial blood lactate levels). ^a No validated threshold presently exists.	IIa	B	213,542,543
It is recommended that a minimal value of DO ₂ of 280 ml/min/m ² be used to reduce the risk of AKI stage 1.	I	A	533–536,545,546
Pump flow rates calculated on the basis of lean body mass may be considered as a suggested lower value in patients with obesity.	IIb	B	528

Recommendation Table 5 Recommendations for the use of carbon dioxide flush

Recommendations	Class ^a	Level ^b	Ref ^c
It is recommended that CO ₂ flush of the CPB circuit before priming is established as the standard of care to reduce GME.	I	B	47,48
CO ₂ insufflation of the operative field may be considered to reduce emboli.	IIb	B	71
When CO ₂ insufflation of the surgical field is used, it is recommended that gas flow be adapted to avoid hypercapnic acidosis.	I	C	-

Recommendation Table 43 Recommendations for goal-directed perfusion

Recommendations	Class ^a	Level ^b	Ref ^c
GDP is recommended to reduce the postoperative rate of early stages of acute kidney injury.	I	A	545,546,568
It is recommended that GDP be aimed at limiting the nadir of DO ₂ and the length of CPB time with low DO ₂ values.	I	B	570–572
It may be considered that individualized DO ₂ based on preoperative risk factors, peripheral oxygenation and pulse pressure, be identified preoperatively and maintained during CPB.	IIb	B	570,574
It should be considered to maintain GDP with a lower threshold of DO ₂ between 280 and 300 ml/min/m ² during normothermic CPB in order to improve clinical outcomes.	IIa	B	568–571